Jefferies 2017 London Healthcare Conference 2017 London Healthcare Conference London, UK November...

Jefferies 2017 London

Healthcare Conference

London, UK

November 15-16, 2017

Company Presentation

Fredrik Tiberg, President & CEO

Forward-looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements

2

Late-stage pipeline and emerging

European commercial organization

Innovation that delivers

‒ Leading technology platform, FluidCrystal®

‒ Late-stage product pipeline with 10 clinical programs

‒ Emerging European commercial organization

‒ Strong pharma partners

Patient centric product development

‒ Long-acting medications for better treatment outcomes and quality of life for patients

‒ Focus on attractive, underserved specialty markets

Entrepreneurial company

‒ Experienced management team

‒ 70 employees with 48 in R&D

‒ Headquarter in Lund, Sweden

‒ Listed on NASDAQ STO (OM-CAMX)

CASH

~45MILLION USD

END Q3 2017

MARKET CAP

470MILLION USD

3

Strong delivery of results during the past year

• Positive Phase 2 opioid blockade results

• Positive Phase 2 results in OUD patients with chronic pain

• Completed patient recruitment to pivotal Phase 3 chronic pain and safety extension study

CAM2038 – OPIOID USE DISORDER (OUD) & CHRONIC PAIN

• Advisory Committee recommendationfor CAM2038 NDA approval

• EMA/TGA validation of MAA submissions

• Priority Review by FDA

• Positive Phase 3 long-term safetystudy results

• Positive Phase 3 efficacy results

OTHER PIPELINE PROGRAMS

• Phase 1 study of CAM2047 and CAM2058 for nausea and pain completed

• Positive initial Phase 1 study results for weekly setmelanotide for genetic obesity disorders

• Positive Phase 2 study results for CAM2029 in acromegaly and NET

4

5

FluidCrystal® injection depot

for longer lasting treatment effects

FluidCrystal® key attributes

Easy and convenient administration

Rapid onset & long-acting release

Good safety profile

Applicable across substance classes

Standard manufacturing processes

Time

+400 PATENTS &

APPLICATIONS

~1500 SUBJECTS HAVE RECEIVED

>15,000 INJECTIONS IN

CLINICAL TRIALS

Liquid drug product

formulation before injection:

SPC+GDO+solvent+Drug

Water absorption

Solvent release

Drug release

Liquid Crystal (LC)

Injection

Depot biodegradation to

complete resolution

Diversified, late-stage pipeline

66

Value adding partnerships

CAM2038, CAM2048, CAM2058 CAM2029, CAM4071 + other products CAM4072

Field Opioid use disorder (OUD) and painAcromegaly, neuroendocrine

tumors and other indicationsGenetic obesity

Scope

• Exclusive license agreement for

North America; option to China,

Japan, Korea, and Taiwan

• Exclusive, worldwide, collaboration and

license agreement

• Exclusive license to FluidCrystal®

Injection depot for setmelanotide

Financials

• MUSD 20 received in upfront

license fee

• Development milestones, include;

○ MUSD 35 for OUD

○ MUSD 21 for chronic pain

• Mid teen % royalties on sales

+ MUSD 75 in potential sales

milestones

• MUSD 50 received in upfront, option

exercise and development milestones

• MUSD 700 in total potential development

and sales milestones

• Mid to high single digit % royalties on sales

• MUSD 65 in development and

sales milestones

• Mid to mid-high single digit %

royalties on sales

“New Hope in The Search for Treatment

for Obesity”, WSJ, August 26, 2016”

7

Weekly and monthly buprenorphine depots

Changing the treatment paradigm in opioid dependence

CAM2038

9

Why focus on opioid dependence?

Growing global public health crisis

• Largest society burden of all drugs1

• 4 million diagnosed patients in the US and Europe, less than half in treatment2,3

• Escalating opioid overdose deaths in the US, Europe and Australia3,4

Investment in treatment adds significant value

• Up to 12 dollars saved for each dollar spent on treatment5

High unmet medical need

• Treatment adherence

• Relapse and overdose

• Burden of daily medication

• Medication diversion and misuse

• Exposure to children and teenagers

• Controls and supervision

• Access to treatment

Concentrated, accessible target prescriber base

~8,000 US

~7,500 Europe

Large, growing market

• 2.7 billion USD in 20166

• Growing at 23% CAGR

• Clear unmet need makes opportunities for differentiated new products

Source: 1. UNODC, World Drug Report 2015; 2. SAHMSA, National Survey on Drug Use and Health (NSDUH) – 2014; 3. EMCDD, European Drug Report Trends and Developments 2017;

4. Hser et al. Harvard Review Psychiatry1 2015; 23: 76-89; 5. Center for Disease Control & Prevention 2016; 6. QuintilesIMS National Sales Perspectives (NSP) June 2017

33,000OPIOID OVERDOSE

DEATHS IN THE US

20154

7000OPIOID OVERDOSE

DEATHS IN

EUROPE 20153

EACH DAY

>1000RECEIVE EMERGENCY

ROOM TREATMENT DUE

TO NONMEDICAL USE

OF OPIOIDS (US)

Unique characteristics of CAM2038

• Weekly and monthly dosing alternatives

‒ Multiple dose strengths

‒ Small volume doses from 0.16 to 0.64 mL

‒ Thin 23G, ½” needle

• Administered by healthcare provider

‒ Ensuring medication adherence and exposure

‒ Minimizing risk of misuse, abuse, diversion and accidental pediatric exposure

• Allows for individualized dosing

‒ Aligning with current treatment guidelines

‒ Use across all phases of medication assisted treatment (MAT) of opioid dependence

10

CAM2038 – individualized treatment of opioid

dependence across treatment phases

Proposed indication:

For treatment of opioid dependence, including treatment initiation.

”New to treatment” patients

Patients in treatment

Transmucosal

buprenorphine

Inititation

(induction)Stabilization

Maintenance

treatment

Weekly

CAM2038Weekly

CAM2038Monthly

or Weekly

CAM2038

11

Potential to significantly improve opioid dependence

treatment with weekly and monthly depots

Sustained suppression of cravings

and withdrawal

Opioid blockade from

first dose

Reduce burdens of

daily medication

Improve treatment adherence

Significantly reduce illicit opioid use

Minimize risks of diversion, misuse and

pediatric exposure

12

13

CAM2038 development milestones in

opioid dependence

Comprehensive clinical program completed

944 participants across 7 clinical studies

Four phase 1/2 studies of pharmacokinetics and pharmacodynamics after single and repeated dosing of CAM2038

Phase 2 opioid blocking study

Phase 3 double-blind, double-dummy, active-controlled study

Phase 3 long-term safety study

May 2017

Positive phase 3

long-term safety

data

July 2017

NDA submission

to FDA

Sept 2017

Priority review

granted by FDA

MAA validation

by EMA

Nov 2017

Recommendation of approval

from FDA Advisory Committee

TGA acceptance for evaluation

of Australian MAA

Jan 2018

PDUFA date set to

19 January 2018

EMA & TGA

MAA approval

decisions

Q3/Q4 2018

14

PharmacokineticsFour clinical trials in healthy volunteers and opioid

dependent patients

PharmacodynamicsA double-blind, randomized within-patient, opioid

challenge study in adults with moderate-to-severe

opioid use disorder

Phase 3 efficacyA 24-week, randomized, double-blind, double-dummy

study assessing efficacy and safety of CAM2038

versus daily SL buprenorphine/naloxone

Phase 3 long-term safetyA 48-week, multinational, open-label study assessing

long-term safety and efficacy of CAM2038

CAM2038 clinical program

Drug liking visual analogue scale

15

Sustained withdrawal suppression and opioid blockade

from the first dose – no need for sublingual medication

0

3

6

9

12

48

To

tal C

OW

S S

co

re

BL 1 2

Treatment Days

3 4 5 6 7 8 9 10 11 12 13 14

Weekly

CAM2038

Injection 2

Weekly

CAM2038

Injection 1

CAM2038 24 mg

CAM2038 32 mg

*

0

40

50

70

80

100

Pe

ak S

co

re (

mm

)

0 6 18

Hydromorphone (mg, IM)

0 6 18 0 6 18 0 6 18 0 6 18

Qualification (Days 1-3) (Days 4-6) (Days 8-10) (Days 11-13)

Weekly

CAM2038

Injection 1

60

90

* 11 pt. difference: Prespecified complete blocking criteria

Neutral

Strong

Disliking

Strong

Liking

Weekly

CAM2038

Injection 2

CAM2038 24 mg

CAM2038 32 mg

Clinical opiate withdrawal scale (COWS)

Phase 3 randomized, double-blind, double-dummy efficacy study (HS-11-421), N=428

Head-to-head efficacy study of a long-acting injection

versus daily sublingual buprenorphine/naloxone

Screening Phase 1: Weekly Visits Phase 2: Monthly Visits Follow-Up

3 Weeks 12 Weeks 12 Weeks 1 Month

Treatment-seeking adults

with opioid use disorder

SL BPN/NX8-24 mg/day

Weekly CAM2038 Placebo

SL BPN/NX8-32 mg/day

Monthly CAM2038 Placebo

SL PlaceboWeekly CAM2038

8-32 mg/week

SL PlaceboMonthly CAM203864-160 mg/month

R

16

17

Phase 3 study in unstable patients – reflecting

real-world opioid dependence patients

Study with high portions of heroin, poly-drug and injection users

SL BPN/NX

(n=215)

CAM2038

(n=213)

Age, years 38 (10.9)* 39 (11.2)*

Male 142 (66%) 121 (57%)

White 164 (76%) 159 (75%)

Body mass index, kg/m2 26 (5.6)* 26 (5.0)*

Employed full time or part time 72 (34%) 76 (36%)

History of any arrest 144 (67%) 130 (61%)

Primary opioid of use

Heroin 151 (70%) 152 (71%)

Prescription opioids 64 (30%) 61 (29%)

SL BPN/NX

(n=215)

CAM2038

(n=213)

Injection opioid use 110 (51%) 114 (54%)

Non-opioid drug use at screening

Total non-opioid drug use 149 (69%) 155 (73%)

Amphetamine 32 (15%) 38 (18%)

Benzodiazepine 35 (16%) 30 (14%)

Cocaine 53 (25%) 53 (25%)

Marijuana 64 (30%) 57 (27%)

Opioid craving; need to use VAS

score (0–100)

76 (24.9)* 77 (25.4)*

Clinical opiate withdrawal scale

score (0-48)

12 (6.0)* 12 (5.4)*

Subjective opiate withdrawal scale

score (0-64)

31 (16.1)* 32 (15.4)*

* Mean (SD)

18

CAM2038 met primary and secondary endpoints of

noninferiority and superiority versus daily SL BPN/NX

Noninferiority shown for mean % urines negative for illicit opioids and response rateP<0.001

Superiority demonstrated for key secondary endpoint of percentage weeks abstinent, P=0.004

-0,2 -0,1 0 0,1 0,2

Treatment difference mean (95% CI)

Favors CAM2038Favors SL BPN/NX

10%

11%

NI margin

NI margin

-0.1% 6.7% 13.3%

-3.5% 3.4% 10.4%

EMA:- Mean % Urine Samples Negative for Illicit Opioids

FDA:Primary Endpoint - Response Rate

0

20

40

60

80

100

CAM2038 SL BUP/NX

100%

75%-<100%

50%-<75%

25%-<50%

1%-<25%

0%

Percent urine samples confirmed

by self-reports negative for illicit

opioid use weeks 4-24.

1 2 3 4 5

Much

Worse

Slightly

Worse

About the

Same

Slightly

Better

Much

Better

19

CAM2038 well tolerated with a low frequency of

injection site adverse events

Mild to moderate local AEs

17%

5%0%

13%6%

0%0

20

40

60

80

100

Mild Moderate Severe

Inje

ctio

nsite

rea

ction

s(%

)

Severity

SL BPN/NX (N=215)

CAM2038 (N=213)

CAM2038 safety profile

Consistent with well established safety profile of SL buprenorphine

Good local tolerability with low frequency of mild to moderate injection site reactions

No unexpected safetyfindings

Transfer from SL BN

High satisfaction indicated by patients transferred from SL BPN to CAM2038 (N=133)

83%

Dissemination of CAM2038 data in publications and

at scientific conferences

2017 2018

Q1 Q2 Q3 Q4 Q1 Q2

Global

Conferences

European

Conferences

National

Conferences

Publications

ISAM

26-29 Oct

Abu Dhabi, UAE

20

Advances in Therapy

Albayatny et al,

2017: 34(2), 560-575

J. Subst. Abuse Treat.

Haasen et al,

2017: 78, 22-29

JAMA Psychiatry

Walsh et al,

2017: Published online

Phase 3 publications in progress

CPDD

17-22 Jun

Montréal,Canada

ISAM

26-29 Oct

Abu Dhabi, UAE

AMERSA

3-5 Nov

Washington DC

AAAP

8-11 Dec

San Diego, USA

ASAM

12-15 Apr

San Diego, USA

IOTOD

17-18 May

Berlin, Germany

Lisbon Addictions

24-26 Oct

Lisbon, Portugal

EUROPAD

25-27 May

Krakow, Poland

ALBATROS

31 May – 2 Jun

Paris, France

ATHS

17-20 Oct

Biarritz, France

SSA

9-10 Nov

Newcastle, UK

APSAD

12 -15 Nov

Melbourne, Australia

21

Limited competition on long-acting injectable opioid

dependence market

CAM2038 Weekly & Monthly

RBP-6000 Monthly

Buprenorphine Depot1

HTX-0032

Vivitrol $300M expected 2017 sales

PDUFA

Jan. 19, 2018

PDUFA

Nov. 30, 2017

Approved in 2010

for OUD

1. Data of first single-ascending dose cohort from Phase I study expected to be released in Q4 2017; 2. No progress updates since 2015.

Long-acting buprenorphine injectables

Long-acting naltrexone

Braeburn/Camurus

Indivior

BDSI

Heron

Alkermes

PRECLINICAL PHASE I PHASE II PHASE III REGISTRATION APPROVAL (US) APPROVAL (EU/Aus)

Estimated

Q3/Q4 2018

Global commercialization strategy for CAM2038

Braeburn markets Braeburn option rightCamurus markets

2.5 milliondiagnosed opioid

dependent in the US2

1.3 millionopioid problem users

in Europe1

187,000opioid dependent

in Australia3

1.4 miilionregistered heroin users

in China4

22Source. 1. Data for 2010 by Degenhardt et al., Addiction, 2014; 109, 1306–1317. 2. EMCDD, European Drug Report 2015 2. SAHMSA, National Survey on Drug Use and

Health (NSDUH) – 2014 3. MedicineToday 2015; 16(6 Suppl):10-15 4. Beijing Review, War on drugs, No.28,July 9,2015

Estimated 15 million opioid dependent individuals globally1

Cost is driven primarily by expensive catastrophic events

23

OUD is a significant driver of direct costs for

payers in the US

$3 435

$19 333

$0

$5 000

$10 000

$15 000

$20 000

$25 000

Any Patient* OUD Patient

Average Per-Patient Costs (2015)

*Including OUD Patients

690,000OUD INTENSIVE CARE UNIT

ADMISSIONS IN 2015

$92,400MEAN OUD ICU

ADMIT COST IN 2015

$63.8 bnCOSTS TO PAYERS

5.6xHIGHER

COSTS

Sources: Fair Health, The impact of the Opioid Crisis on the Healthcare System, 2016.; Yokell MA, et al. Presentation of Prescription and Nonprescription Opioid Overdoses to US Emergency

Departments, 2014.; Stevens, et al. The critical care crisis of opioid overdoses in the United States, 2017.

24

Prescription volume growth of OUD treatment in the US.

Significant market share expected for long-acting buprenorphine

8 040

9 309 10 327

11 149 12 035

13 156

0

5 000

10 000

15 000

2012 Q2 2013 Q2 2014 Q2 2015 Q2 2016 Q2 2017 Q2

TR

xV

olu

me

(0

00

s)

Total TRx Volume 12 Months ending June1

Source: 1. Symphony Health, PHAST Integrated Monthly; 2. Jefferies, RBC Capital, Numis, Stifel, Merrill Lynch

buprenorphine/naloxone

(Suboxone, Bunavail, Zubsolv & oral generics)buprenorphine HCL & generics

naltrexone (Vivitrol)

ANALYSTS:

$0.8-1.4 bnUS PEAK SALES ESTIMATES FOR

MONTHLY BUPRENORPHINE DEPOT

PRODUCT FOR OUD2

Spain

61,954

France

161,388

UK

148,686Germany

77,500

Nordic countries

16,535

Italy

75,964

25

Preparing for 2018 launch of

CAM2038 in Europe and Australia

Ongoing pre-launch activities

• HEOR, pricing and market access

• Strategic marketing

• Medical affairs

• Policy and education

• Country operating models

Internationally experienced leadership team

• Market access, medical affairs, global commercial strategy, opioid dependence & pain

Establishment in key European markets

Headcount build-up following to launch sequence

Strong rationale for CAM2038 in Europe and Australia

• Specialist market with a concentrated prescriber base

• High unmet medical needs

• No significant innovation for more than a decade

• Paradigm shift in opioid dependence treatment

• Pricing and reimbursement supported by sizeable health and socio-economic benefits

26

Large interest in CAM2038 among physicians and

large patient pool in Europe and Australia

Large markets & high willingness to prescribe depots gives market estimates for depot of €180m-€250m2

Country Physicians willingness to prescribe CAM20381 % patients*: q4w q1w

86%

94%

86%

96%N=50

N= 47

31%

30%

36%

25%

N= 4843%

27%

39%

22%

N=51

N=50

N=50

Patient numbers in EU5, Nordics and Australia

0

50000

100000

150000

200000

No.s in substitution treatment

New entrants to treatment

Estimated no. of buprenorphine

Source. 1. Market access dynamics in opioid addiction, Decision Resources 2015 * % patients considered suitable for CAM2038 by surveyed physicians if available on the market: 2. Europe and Australia

Round-the-clock relief of chronic pain withlimited potential for misuse and diversion

CAM2038

28

Chronic pain is a global health problem with large

impact on patients’ QoL and society

Opioids are highly effective in management of chronic pain, but come at a high price

Side effects, dose escalation, misuse, abuse, diversion, opioid overdoses and pediatric exposure

Over 15,000 US overdose deaths related to prescription pain relievers (2015)6

1 IN 5 INDIVIDUALS SUFFERING FROM CHRONIC PAIN1

The chronic pain global health challenge Opioids for chronic pain

Sources. 1. Current Medical Research & Opinion Vol. 26, No. 5, 2010, 1231–1245; Disease Landscape and Forecast Chronic Pain, Decision Resources 2015; 2. Relieving Pain in America, A Blueprint for Transforming

Prevention, Care, Education and Research. The National Academic Press 2011; 3. Eur J Pain 2006;10:287-333 4. Journal of Pain 2012, 13:715-724; 5. Persistence Market Research 2016; 6. Prescription Opioid

Overdose Data, CDC 7. Symphony Health Solutions, data period: November 2015, January 2016;

~200 MILLION

PEOPLE

SUFFER FROM CHRONIC

PAIN IN EU & US2,3

$ 560-635

BILLIONS

COST TO SOCIETY4

LARGE

NEGATIVE

IMPACT ON

QoL5

• 24% of opioid chronic pain prescriptions were for 90 mg/day or higher morphine equivalent doses in 20157

• Global opioid analgesics market worth 6.2 bn USD1

• New recommendations, updated guidelines and regulations leave many patients without effective treatment alternatives

Buprenorphine has uniqueproperties for pain management

Rational for CAM2038 in treatmentof chronic pain

29

• Category 3 opioid with lowerpotential for dependence

• Provides effective dosedependent pain relief

• 25-100 times more potent thanmorphine

• Favorable safety profile with a ceiling effect on respiratorydepression

• Less dysphoria and no evidence ofhyperalgesia

• Less analgesic tolerance

Round the clock pain relief

Multiple weekly and monthllydoses allow dose titration and individualized treatment

Rapid and sustained blockade ofeuphorigenic and sedativeopioid effects

HCP administration adressesmisuse and diversion issues

A majority of physicians whotreat addiction also treat pain

Clear rational for buprenorphine depots for chronic pain,

further emphasized in high risk/high dose patients

Sources. Anesthesiology 2014; 120:1262-74, J Clin Pharm Ther. 2014 Dec;39(6):577-83

µ-opioid receptor agonist

κ-opioid receptor antagonist

No

activation

BuprenorphineMorphine

Illustrative

Full agonist Partial agonist

Double-blind, enriched-enrollment study in opioid experienced low back pain patients on morphine equivalent doses of 40 mg/day or higher (Nest.=340)

Recruitment completed in pivotal Phase 3 chronic pain

study and safety extension studies of CAM2038.

Topline data expected early 2018

30

Screening Transition Double-Blind treatment Follow-Up

2 Weeks Up to 10 Weeks 12 Weeks 4 weeks

Moderate tosevere lowerback pain, patients onhigh daily

dose of opioids(incl SL BPN)

CAM2038 q1w8-32 mg/week

Titrated to effecton a stable dose of

CAM2038

CAM2038 Placebo

CAM2038 q1w 8 -12 mg/day orCAM2038 q4w 64-128 mg/day

R

Open-label titration

2 Weeks

Down-titrationof opioid dose and

transitionedto IR morphine

(only if noton SL BPN)

Primary and key secondary endpoints:

Average and worst pain intensity as measured by 11-point numerical rating scale

Pipeline expansion with additional

attractive early stage candidates

PARTNER PRODUCT PRE-CLINICAL PHASE1-2

31

PHASE 1-2

PHASE 1-2

CAM2029 ACROMEGALY

CAM2029 NEUROENDOCRINE TUMORS

PHASE 1-2CAM2032 PROSTATE CANCER

CAM4072 GENETIC OBESITY

CAM2043 PULMONARY ARTERIAL HYPERTENSION

Undisclosed internal project candidates

Early stage collaborations with pharma and biotech partners

PHASE 1-2PHASE 1-2

PHASE 1-2

PHASE 1-2

CAM2047 CHEMOTHERAPY INDUCED NAUSEA & PAIN

CAM2048/2058 POSTOPERATIVE PAIN & POSTOPERATIVE NAUSEA & PAIN

32

Pipeline products overview – CAM2029

CAM2029

TARGET

INDICATIONS Acromegaly and neuroendocrine tumors

FORMULATION Subcutaneous octreotide depot based on FluidCrystal®

KEY

ADVANTAGES• Improved patient convenience

• Increased bioavaiability

• potential for enhanced treatment efficacy in currently

underexposed patients

MARKET SIZE Somatostatin analogue market >$2 bn1

DEVELOPMENT

STATUS• Four phase 1/2 trials successfully completed

• Novartis currently evaluating new study designs recently

suggested by health authorities

• Ongoing preparations for Phase 3 including additional

manufacturing and packaging activities

PARTNER Novartis (exclusive worldwide license)

Sources. 1. GlobalData 2017; 2. GBI Research 2010

Somatostatin analogue sales

Significant potential in converting

Sandostatin® LAR ® patients to CAM2029

33

Pipeline products overview – CAM2047 and CAM2048/58

CAM2047

TARGET

INDICATION

Chemotherapy induced nausea and vomiting

(CINV)

FORMULATION SC granisetron FluidCrystal® depot

KEY ADVANTAGES • ~5-7 days duration to cover both acute and

delayed CINV

• Ready-to-use prefilled syringe

• Room temperature storage

MARKET SIZE $1 bn1 for NK1 and 5HT-3 inhibitors

DEVELOPMENT

STATUS

• Phase 1 completed

• Preparations for Phase 3 ongoing

KEY RESULTS PK and tolerability targets met in Phase 1

PARTNER Partnering strategy under evaluation

CAM2048/58

TARGET

INDICATION

Acute pain (post-operative) and post-operative

nausea and vomiting (PONV)

FORMULATION SC FluidCrystal® depot of buprenorphine (CAM2048)

or buprenorphine/granisetron (CAM2058)

KEY ADVANTAGES • Continuous pain relief ~4 days to cover post-

operative pain (and nausea & vomiting)

• Controlled administration by HCP (no diversion or

misuse)

MARKET SIZE Post-operative pain market >$5 bn2

DEVELOPMENT

STATUS


• Preparations for Phase 3 ongoing


PARTNER Braeburn Pharmaceuticals (North America)

CAM2048/58

TARGET

INDICATION








misuse)


DEVELOPMENT

STATUS


• Pivotal study program in prepara



CAM2048/58

TARGET

INDICATION








misuse)


DEVELOPMENT

STATUS


• Pivotal study program in preparation



Sources. 1. GlobalData 2017; 2. GBI Research 2010

CAM4072

TARGET

INDICATION

Genetic obesity disorders

FORMULATION Subcutaneous setmelanotide depot based on

FluidCrystal®

KEY

ADVANTAGES

• Weekly dosing

• Ready-to-use prefilled syringe

• Improved patient convenience

MARKET SIZE Not communicated

DEVELOPMENT

STATUS

• Phase 1 results expected Q4 2017

• Submission earliest 20191

KEY RESULTS Positive initial phase 1 results meeting Rhythm’s

PK and tolerability criteria.

PARTNER Rhythm (exclusive worldwide license)

34

Pipeline products overview – CAM4072 and CAM2043

CAM2043

TARGET

INDICATION

Pulmonary arterial hypertension (PAH)

FORMULATION Subcutaneous treprostinil depot based on

FluidCrystal®

KEY

ADVANTAGES

• ~7 days duration

• No need for extracorporal pump and infusion

hoses

• Potential for reduced injection site pain and

local reactions

• Lower risk of infections and sepsis

MARKET SIZE PAH market >$5 bn, tresprostinil ~1.2 bn2

DEV. STATUS • Planned phase 1 start Q4 2017

KEY RESULTS Preclinical target PK profile confirmed

Sources. 1. Form S-1 Rhythm Pharmaceuticals 2017 2. PharmaCircle 2017

• Potential levers for future value creation

‒ NDA/MAA approvals of CAM2038 in the US/EU

‒ Phase 3 programs in pain, acromegaly and NET

‒ Advancement of early stage clinical programs

‒ Pipeline expansion and business development

• Anticipated CAM2038 launch in 2018

‒ Braeburn launch US H1 2018

‒ Camurus launch Europe Q4 2018

‒ Geographical expansion in 2018/19

• Solid financial position

‒ Potential for significant near-term regulatory milestone payments, and royalty from sales

Camurus positioned for continued value creation

• De-risked, late stage, differentiated pipeline

‒ Multibillion dollar specialty markets

‒ Opioid addiction, pain, cancer, endocrine disease

• Strong collaborations with dedicated partners

‒ Novartis, Braeburn Pharmaceuticals, Rhythm, Solasia

‒ Early project collaborations with global pharma companies

• Emerging commercial organization

‒ Strong, internationally experienced leadership

35

Camurus AB, Ideon Science Park, SE-223 70 Lund, Sweden

[email protected] camurus.com

Experienced and committed management team

Fredrik Tiberg, PhD, Prof.

President & CEO

In Company since: 2002

Holdings: 1,512,551 shares & 130,000 subsc. warrants

Education: M.Sc. in Chemical Engineering, PhD in

Physical Chemistry, Lund University

Previous experience: Professor in Physical

Chemistry at Lund University, Institute for Surface

Chemistry (Section head), Visiting Professor at

Oxford University

Eva Pinotti-Lindqvist Chief Financial Officer


Holdings: 36,391 shares & 25,882 subscript. warrants

Education: Bachelor’s of Science in Economics,

Lund University

Previous experience: EQL Pharma (CFO), Nordic

Drugs (Nordic Market Analyst), Poolia (Finance

Consultant)

Richard Jameson

Chief Commercial Officer


Holdings: 16,395 shares & 80,000 subscript. warrants

Education: Bachelor’s of Science in Applied

Biological Sciences from University West of England

Previous experience: GM, UK and Nordics for

Reckitt Benckiser Pharmaceuticals Ltd (2010 –

2013) and Area Director Europe, Middle East and

Africa for Indivior PLC (2013 – 2016).

Fredrik Joabsson, PhD Vice President, Business Development

In Company since: 2001Holdings: 36,391 shares & 20,000 subscription warrants

Markus Johnsson, PhD Vice President, Pharma-ceutical & Analytical Dev.


Margareta Linden, PhD Vice President, Project Management

In Company since: 2004Holdings: 36,291 shares & 25,000 subscript. warrants

Torsten Malmström, PhD Vice President, Technical Operations


Rein PiirVice President, Investor Relations

In Company since: 2015Holdings: 5,275 shares

Agneta SvedbergVice President, Clinical & Regulatory Development


Urban PaulssonVice President Corporate Dev.& General Counsel

In Company since: 2017Holdings: 6,500 shares & 75,000 subscript. warrants

Education: Master of Law from Lund University

Previous experience: More than 20 years

experience from the life science industry including as

legal counsel at Pharmacia and general counsel for

Vitrolife. Partner at law firms Bird & Bird and

Nordia Law.

Cecilia CallmerVice President, Human Resources

In Company since: 2017Holdings: 17,650 subscription warrants

37

Jefferies 2017 London Healthcare Conference 2017 London Healthcare Conference London, UK November...

Documents

Transcript of Jefferies 2017 London Healthcare Conference 2017 London Healthcare Conference London, UK November...